The Rezum procedure in benign prostate hyperplasia: Initial experience at a single center in Turkey

Yıl 2023, Cilt: 15 Sayı: 1, 23 - 29, 30.01.2023

Mert Kılıç , Mevlana Derya Balbay

https://doi.org/10.54233/endouroloji.1217490

Öz

Objective: In this study, we aimed to present our initial experiences with the Rezum procedure, including voiding and sexual outcomes.
Material and Methods: A total of 24 patients who underwent the Rezum procedure between June 2021 and August 2022 were included in this retrospective study. For each procedure, 2 to 12 injections were applied to the median and lateral prostate lobes. We analyzed the baseline and follow-up data and compared the outcomes of patients with and without the median lobe of the prostate.
Results: The mean follow-up time was 7.5 months. The International Prostate Symptom Score decreased in all patients by 15 points on average (p<0.001), while the maximum urinary flow increased by 5 mL/s on average in all patients except three who had similar values (p<0.001). The post-void residual decrease was 55 mL (p<0.001). In terms of the variables examined, there was no significant difference between patients who had a median lobe and those who had not. Neither any sexual worsening nor any major complications were observed. As for minor complications, two patients had macrohematuria, four had dysuria that required non-steroidal anti-inflammatory drug therapy, and two required re-catheterization due to urinary retention.
Conclusion: The Rezum procedure is an effective and practical method, even in patients who have median lobes of the prostate, and preserves sexual functions.

Anahtar Kelimeler

Lower Urinary Tract Symptoms, Minimally invasive surgery, Prostatic Hyperplasia, Rezum

Benign prostat büyümesinde Rezum prosedürü: Türkiye’den tek merkezli ilk deneyimlerimiz

Öz

Amaç: Bu çalışmada üriner ve cinsel sonuçlar dahil olmak üzere Rezum prosedürü ile ilgili ilk deneyimlerimizi sunmayı amaçladık.
Gereç ve Yöntemler: Bu retrospektif çalışmaya Haziran 2021 ile Ağustos 2022 arasında Rezum işlemi uygulanan toplam 24 hasta dahil edildi. Her prosedür için prostatın lateral ve varsa medyan loblarına 2 ila 12 enjeksiyon uygulandı. Başlangıç ve takip verileri analiz edildi. Ayrıca prostat medyan lobu olan ve olmayan hastaların sonuçları da karşılaştırıldı.
Bulgular: Ortalama takip süresi 7,5 aydı. Uluslararası Prostat Semptom Skoru tüm hastalarda ortalama 15 puan azalırken (p<0,001), maksimum idrar akışı benzer değerlere sahip üç hasta dışında tüm hastalarda arttı (ortalama 5 mL/s) (p<0,001). İşeme sonrası rezidüel idrarda azalma ise ortalama 55 mL idi (p<0,001). Medyan lobu olan ve olmayan hastalar arasında hiçbir değişken için anlamlı fark yoktu. Hiçbir hastada herhangi bir cinsel kötüleşme ya da majör bir komplikasyon gözlenmedi. Minör komplikasyon olarak, iki hastada makrohematüri, dördünde non-steroidal antiinflamatuar ilaç tedavisi gerektiren dizüri ve iki hastada idrar retansiyonu nedeniyle tekrar kateterizasyon saptandı.
Sonuç: Rezum işlemi prostat medyan loblu hastalarda dahi cinsel fonksiyonları koruyan etkili ve pratik bir prosedürdür.

Anahtar Kelimeler

Alt üriner sistem semptomları, Prostat büyümesi, Minimal invaziv tedavi, Rezum

Kaynakça

• 1. Barry MJ, Fowler FJ, Jr., O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549-57; discussion 64. https://doi.org/10.1016/s0022-5347(17)36966-5
• 2. Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016;43(3):289-97. https://doi.org/10.1016/j.ucl.2016.04.001
• 3. Miernik A, Gratzke C. Current Treatment for Benign Prostatic Hyperplasia. Dtsch Arztebl Int. 2020;117(49):843-54. https://doi.org/10.3238/arztebl.2020.0843
• 4. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol. 2015;67(6):1099-109. https://doi.org/10.1016/j.eururo.2014.12.038
• 5. Dixon CM, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, et al. Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Res Rep Urol. 2016;8:207-16. https://doi.org/10.2147/rru.s119596
• 6. Dixon C, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, et al. Efficacy and Safety of Rezūm System Water Vapor Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Urology. 2015;86(5):1042-7. https://doi.org/10.1016/j.urology.2015.05.046
• 7. Darson MF, Alexander EE, Schiffman ZJ, Lewitton M, Light RA, Sutton MA, et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res Rep Urol. 2017;9:159-68. https://doi.org/10.2147/rru.s143679
• 8. Woo HH, Gonzalez RR. Perspective on the Rezūm(®) System: a minimally invasive treatment strategy for benign prostatic hyperplasia using convective radiofrequency water vapor thermal therapy. Med Devices (Auckl). 2017;10:71-80. https://doi.org/10.2147/mder.s135378
• 9. McVary KT, Gittelman MC, Goldberg KA, Patel K, Shore ND, Levin RM, et al. Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol. 2021;206(3):715-24. https://doi.org/10.1097/ju.0000000000001778
• 10. Whiting D, Noureldin M, Abdelmotagly Y, Johnston MJ, Brittain J, Rajkumar G, et al. Real-world Early Outcomes and Retreatment Rates Following Water Vapour Ablative Therapy for Symptomatic Benign Prostatic Hyperplasia. Eur Urol Open Sci. 2022;39:72-8. https://doi.org/10.1016/j.euros.2022.03.006
• 11. McVary KT, Rogers T, Roehrborn CG. Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. Urology. 2019;126:171-9. https://doi.org/10.1016/j.urology.2018.12.041
• 12. Bole R, Gopalakrishna A, Kuang R, Alamiri J, Yang DY, Helo S, et al. Comparative Postoperative Outcomes of Rezūm Prostate Ablation in Patients with Large Versus Small Glands. J Endourol. 2020;34(7):778-81. https://doi.org/10.1089/end.2020.0177
• 13. Babar M, Loloi J, Tang K, Syed U, Ciatto M. Emerging outcomes of water vapor thermal therapy (Rezum) in a broad range of patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review. Low Urin Tract Symptoms. 2022;14(3):140-54.
• 14. Doppalapudi SK, Gupta N. What Is New with Rezūm Water Vapor Thermal Therapy for LUTS/BPH? Curr Urol Rep. 2021;22(1):4. https://doi.org/10.1111/luts.12435
• 15. Tzeng M, Basourakos SP, Lewicki PJ, Hu JC, Lee RK. New Endoscopic In-office Surgical Therapies for Benign Prostatic Hyperplasia: A Systematic Review. Eur Urol Focus. 2022;8(2):522-31. https://doi.org/10.1016/j.euf.2021.02.013
• 16. Soans J, Vazirian-Zadeh M, Kum F, Dhariwal R, Breish MO, Singh S, et al. Can surgical treatment for benign prostatic hyperplasia improve sexual function? A systematic review. Aging Male. 2020;23(5):770-9. https://doi.org/10.1080/13685538.2019.1593356